JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

JAK2 inhibitors increase the abundance of EGFR in lung cancer cells, thereby restoring the efficacy of EGFR inhibitors in resistant tumors.